ReviewTherapeutic advances in chronic disease2016
New perspectives on management of idiopathic pulmonary fibrosis.
Review in Therapeutic advances in chronic disease, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 37 citations in OpenAlex.
- Vascular Contribution to Lung Repair and Fibrosis.American journal of respiratory cell and molecular biology · 2023Review
- Phosphodiesterase type 10A inhibitor attenuates lung fibrosis by targeting myofibroblast activation.iScience · 2023Article
- Prognostic Significance of Red Cell Distribution Width in Idiopathic Pulmonary Fibrosis and Combined Pulmonary Fibrosis Emphysema.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2021Article
- Roles of Nrf2 in Liver Diseases: Molecular, Pharmacological, and Epigenetic Aspects.Antioxidants (Basel, Switzerland) · 2020Review
- Aerobic and breathing exercises improve dyspnea, exercise capacity and quality of life in idiopathic pulmonary fibrosis patients: systematic review and meta-analysis.Journal of thoracic disease · 2020Review
- Diosmin ameliorative effects on oxidative stress and fibrosis in paraquat-induced lung injury in mice.Environmental science and pollution research international · 2019Article
- Gastric Acid and Pepsin Work Together in Simulated Gastric Acid Inhalation Leading to Pulmonary Fibrosis in Rats.Medical science monitor : international medical journal of experimental and clinical research · 2019Article
- Epidemiology of Pulmonary Fibrosis: A Cohort Study Using Healthcare Data in Sweden.Pulmonary therapy · 2019Article
- Bleomycin Inhibits Proliferation via Schlafen-Mediated Cell Cycle Arrest in Mouse Alveolar Epithelial Cells.Tuberculosis and respiratory diseases · 2019Article
- Idiopathic pulmonary fibrosis and GERD: links and risks.Therapeutics and clinical risk management · 2019Article
- Retrospective Analysis of Medication Utilization and Clinical Outcomes in Patients With Idiopathic Pulmonary Fibrosis Treated With Nintedanib or Pirfenidone.Clinical medicine insights. Circulatory, respiratory and pulmonary medicine · 2019Article
- Assessment of survival in patients with idiopathic pulmonary fibrosis using quantitative HRCT indexes.Multidisciplinary respiratory medicine · 2018Article
- Pirfenidone attenuates bleomycin-induced pulmonary fibrosis in mice by regulating Nrf2/Bach1 equilibrium.BMC pulmonary medicine · 2017Article
- Hydroxysafflor Yellow A Suppresses MRC-5 Cell Activation Induced by TGF-β1 by Blocking TGF-β1 Binding to TβRII.Frontiers in pharmacology · 2017Article
- Preparation of novel pirfenidone microspheres for lung-targeted delivery: in vitro and in vivo study.Drug design, development and therapyArticle
- Lung Cancer in Patients with Severe Idiopathic Pulmonary Fibrosis: Critical Aspects.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive parenchymal lung disease characterized by a median survival of 3-5 years following diagnosis. The diagnosis is based on clinical, radiological and histopathological evaluation. Therefore, a multidisciplinary team is needed to reach the correct diagnosis. For a long time, supportive care and lung transplantation in selected cases, have been considered the only possible treatments for IPF. In the last decade many studies have investigated IPF pathogenesis, leading to an improved knowledge of the mechanisms underlying the disease and to the approval of two new drugs for IPF treatment (pirfenidone and nintedanib). The therapeutic approach of IPF cannot be limited to the administration of antifibrotic drugs, but it is necessary for improving the quality of life of patients and for facilitating, as far as possible, the performance of normal daily activities and relationships. IPF patients are also afflicted by disease-related complications such as gastroesophageal reflux, pulmonary hypertension, acute exacerbations and an increased risk of developing lung cancer. The clinician who treats IPF patients, should also treat these possible complications to slow disease progression, thus maintaining the possibility of a pulmonary transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.